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have excellent long-term patency, but a short life
expectancy because of the underlying malignancy. In this
report, we updated our experience with patients who
underwent venous reconstructions for benign iliofemoral
or IVC occlusion or for venous trauma in the past 15
years. We analyzed long-term patency and clinical out-
comes to identify factors predicting the success of surgical
reconstructions.
PATIENTS AND METHODS
We retrospectively reviewed the clinical course and
outcome of 42 patients who underwent venous recon-
struction for iliofemoral or IVC occlusion caused by non-
malignant disease at our institution between January 1,
1985, and June 30, 1999. There were 43 patients who
had venous reconstructions performed during this period
for this indication, but one patient denied research autho-
rization. Data for 15 of these patients with shorter follow-
up have been previously reported.8,9 During the same
period, 1639 operations for varicose veins and 96 subfas-
cial endoscopic perforator surgery procedures were per-
formed at the Mayo Clinic.
Clinical presentation and results of preoperative evalu-
ation, including venous pressure measurements and func-
tional studies, were reviewed and recorded. All available
imaging studies were reviewed. 
Patients with chronic occlusion of the inferior vena
cava (IVC) or the iliofemoral veins may present with vari-
ous symptoms, ranging from mild discomfort to severe
disability, including limb swelling and and aching or thigh
and buttock pain, which is induced by exercise (venous
claudication). Signs of venous outflow obstruction include
limb swelling, varicosities, and a range of skin changes
including ulceration. Attempts to reconstruct venous out-
flow obstruction include surgical bypass grafts and
endovascular techniques with angioplasty and stents.1-7
Factors affecting the success of venous surgical bypass
grafts are still not well defined.
We previously reported results of large vein recon-
structions performed at our institution for both benign
and malignant disease.8-11 Patients with malignant disease
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Purpose: Venous reconstructions are rarely performed, and factors affecting long-term results of bypass grafts implanted
in the venous system are not well defined. In this report we updated our experience. 
Methods: The clinical data of all patients who underwent venous reconstruction for iliofemoral or inferior vena caval
(IVC) occlusion due to nonmalignant disease between January 1985 and June 1999 were retrospectively reviewed.
Patients were classified, and outcomes were compared according to the guidelines of the Joint Vascular Societies. 
Results: Forty-two patients, 23 males and 19 females (mean age, 40 years; range, 16-81), underwent 44 venous recon-
structions. Thirty-six patients had limb swelling or venous claudication, 38 had pain, and 14 had healed or active
ulcers. The cause of obstruction was congenital in two and acquired in 40 (deep vein thrombosis, 25; trauma, 5;
retroperitoneal fibrosis, 4; IVC occlusion devices, 4; others, 2). Eighteen patients underwent saphenous vein crossover
grafts (Palma procedure), 17 had expanded polytetrafluoroethylene (ePTFE) grafts implanted (femorocaval, 8; ilio-
caval, 5; crossfemoral, 3; cavoatrial, 1), 6 patients had spiral vein grafts (5 iliac/femoral and 1 cavoatrial), and 1 under-
went femoral vein patch angioplasty. Clinical follow-up averaged 3.5 years (median, 2.5), and graft follow-up with
imaging studies averaged 2.6 years (median, 1.6). Seven patients were lost to follow-up. The secondary 3-year patency
rate for all reconstructions was 62%. Palma procedures had a 4-year patency rate of 83%. The secondary patency rate
of iliocaval and femorocaval ePTFE bypass grafts at 2 years was 54%. The secondary patency was lower in patients with
an arteriovenous fistula (P = .023). All ePTFE grafts had a 45% patency rate at 2 years, not significantly different from
saphenous vein grafts (83%, P = .16). Clinical scores improved with graft patency (median, 0.0 vs 1.5; P = .044).
Conclusions: Venous reconstructions for iliofemoral or IVC obstruction offer 3-year patency rates of 62%. The Palma
procedure with autologous saphenous vein had the best long-term patency, whereas long-term success with ePTFE was
moderate. The use of an arteriovenous fistula to improve graft patency remains controversial. (J Vasc Surg
2001;33:320-8.)
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Follow-up imaging studies were performed in all
patients, and the end point of patency was defined as patent
or occluded at the last imaging study (average, 2.6 years;
median, 1.6 years; range, 1 month to 11.7 years). The last
imaging study was venography (13) or ultrasound scan (29)
(Figs 1 and 2). Primary patency was defined as no graft
intervention for graft occlusion (surgical or endovascular),
and secondary patency was defined as any graft intervention
resulting in graft patency. The average duration of clinical
follow-up was 3.5 years (median, 2.5; range, 0.1-11.7), and
information was obtained from a questionnaire up to a
mean of 6 years (median, 7.1; n = 34; range, 0.6-11.6).
Seven patients were lost to follow-up; however, information
on graft patency in these patients was available at a mean of
25 months after operation (range, 10-62 months). Three
patients died in the follow-up period of unrelated causes,
and on two patients, follow-up information was available
and complete.
The guidelines of the Joint Vascular Societies (CEAP
classification) were used for classification and scoring clini-
cal outcome, and disability.12 The clinical severity score12a
and outcome score12 (asymptomatic, 3; moderate improve-
ment, 2; mild improvement, 1; unchanged, 0; mildly worse,
–1; moderately worse, –2; and severely worse, –3) were used
to assess clinical benefit. Outcome scoring was obtained in
34 patients (81%). The clinical factors of smoking, a clinical
class more than 3, the presence of distal venous reflux, a his-
tory of deep venous thrombosis (DVT), obesity, diabetes, a
history of limb trauma, hypercoagulability, and operative
and anatomic factors were analyzed for associations with
graft occlusion.
Estimates of primary and secondary patency were cal-
culated with the Kaplan-Meier survival method.13 The
95% CIs are given for these estimates. Patency between
patient groups was compared with the log-rank test.14 For
clinical outcome measures at last follow-up, the patients
with occlusion and those without occlusion were com-
pared with the Wilcoxon rank sum test. Results were con-
sidered statistically significant with a P value of .05 or less.
Because of the small number of patients in several sub-
groups, the power of statistical analyses was limited.
RESULTS
Forty-two patients (23 males, 19 females) with a mean
age of 40 years (range, 16-81) underwent 44 venous recon-
structions for nonmalignant occlusion of the iliofemoral veins
or IVC. Signs and symptoms of venous hypertension were
limb swelling or venous claudication in 36 patients; 38 had
pain, 5 had healed ulcers (Class 5), and 9 had active ulcers
(Class 6). Thirty-seven patients (88%) were in Classes 3 to 6.
Four patients had acute venous trauma (Class 0) (Table I).
The etiology of venous obstruction was congenital in
two patients and acquired in 40. Secondary causes included
chronic persistent venous thrombosis in 25 patients, trauma
in 5 (3 iatrogenic and 2 gunshot wounds), retroperitoneal
fibrosis in 4, DVT associated with IVC occlusion devices in
4 (1 Hunter’s balloon, 1 Miles’ clip, and 2 ligations), and
suprarenal caval occlusion in 2 (1 web and 1 IVC coarcta-
tion) (Fig 3). Risk factors for DVT included a previous
DVT in 34 patients, smoking in 21, obesity in 14, a history
of limb trauma in 14, and a prethrombotic state in 5. 
Preoperative conservative management included inter-
mittent leg elevation (35 patients), graded compression
stockings (31 patients), diuretics (10 patients), and Unna
boots or intermittent pneumatic compression pump (3
patients each). Previous surgical interventions in 12
Fig 1. Digital subtraction venogram of left lower extremity and
pelvis showing a patent left to right Palma graft 6 months after
operation (dark arrow). Left iliac vein stent (white arrow) throm-
bosed before operation.
Fig 2. Patent left femorocaval ePTFE bypass graft in a 54-year-
old woman 11.7 years after graft placement (arrow). 
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patients included vein stripping in 5, iliac vein angioplasty
with stenting in 3, angioplasty alone in 1, skin grafting in
2, and previous venous reconstruction in 2. 
Thirty patients had preoperative venous functional
studies: 18 underwent strain gauge plethysmography
(Phlebotest; Eureka, Stockholm, Sweden), and 12 had
impedance plethysmography. Twenty-five patients (83%)
had abnormal results from the studies, suggesting venous
outflow obstruction (> 4-second venous drainage times or
abnormal impedance tracings). Twelve (57%) of 22 patients
had plethysmographic evidence of associated venous incom-
petence as noted by abnormal refill rates (< 5 seconds) or
positive exercise venous plethysmography.15
Preoperative imaging included contrast venography in
38 patients and computed tomography with intravenous
contrast in 10. Duplex scan was used to assess for reflux in
30 patients. Thirty-two patients had iliofemoral venous
occlusion (21 left and 11 right), 6 had iliocaval occlusions,
and 4 were isolated to the IVC. The pathophysiology of
venous disease involved obstruction alone in 20 (48%) and
a combination of obstruction and distal reflux in 22.
Twelve of 14 patients with Class 5 and Class 6 disease had
both reflux and obstruction. Incompetent perforating
veins were noted in seven patients preoperatively.
Surgical indications for venous reconstruction in-
cluded symptomatic venous occlusion despite conservative
management or acute venous injury. Eighteen patients
underwent saphenous vein crossover grafts (Palma proce-
dure), 17 had externally supported expanded polytetraflu-
oroethylene (ePTFE) grafts implanted (femorocaval, 8;
iliocaval, 5; crossfemoral, 3; cavoatrial, 1), 6 had spiral vein
grafts (5 iliac/femoral and 1 cavoatrial), and 1 had a
femoral vein patch angioplasty (Figs 4 and 5). A distal
arteriovenous fistula (AVF) was added at the initial proce-
dure in 20 patients (48%) and at reoperation in an addi-
tional four.
Graft flows were measured with an electromagnetic flow
meter that ranged from 20 to 3000 mL/min (mean, 349;
median, 80) without an AVF and 125 to 2200 mL/min
(mean, 571; median, 300) with an AVF (n = 22). The
median prereconstruction femoral/central (femorofemoral
in patients with unilateral disease) venous pressure gradient
was 10 mm Hg (range, 1-37; n = 25), and it decreased to a
median of 4 mm Hg (range, 0-18 mm Hg; n = 24) as mea-
sured intraoperatively after reconstruction. Pressures were
measured in the supine patient, and adjuncts such as tourni-
quets or drugs were not used during the study. 
Intraoperative anticoagulation was used in all patients
with 5000 units of intravenous heparin, with an additional
dose given if the activated clotting time was less than twice
the normal time. Patients continued to receive 500 U/h
of heparin infusion, either through a catheter placed into
the saphenous or femoral veins and advanced to the prox-
imal anastomosis or through a peripheral or central line.
All but one patient were discharged while receiving oral
anticoagulation. Patients were fitted with thigh-high
graded compression stockings of 30 to 40 mm.
There was no early death, and there were no acute
clinically evident DVTs or pulmonary emboli. Early graft
occlusion occurred in eight patients (19%). Other compli-
cations included bleeding that required surgical evacua-
tion of hematoma or transfusion in five patients (12%) and
local wound infections in three (7%). Twenty-one sec-
ondary procedures were performed, 8 were within 30 days
of grafting, and 13 occurred later during follow-up. Early
interventions included thrombectomy in 6 patients (4
with the addition of an AVF), graft revision in 1, and
wound exploration for hematoma in 1.
The primary patency rate at 30 days for all reconstruc-
tions was 81%, and secondary patency rate was 93%. Of
the 42 patients, 39 (93%) had a patent graft (38) or
venous reconstruction (1 patch angioplasty) at discharge. 
Late graft patency
For all reconstructions, the overall 3-year primary and
secondary patency rates were 54% (CI, 40%-75%) and 62%
Table I. Clinical classification
Preoperative* Postoperative†
Clinical class No (%) No (%)
C0-no signs 4 9.5 4 12
C1-reticular veins 0 0 0 0
C2-varicosities 1 2.4 0 0
C3-edema 19 45.2 12 35
C4-skin changes 4 9.5 7 21
C5-healed ulcer 5 11.9 9 26
C6-active ulcer 9 21.4 2 6
*n = 42.
†n = 34.
Fig 3. Etiology of venous occlusion in the 42 patients studied.
Reprinted by permission from the Mayo Foundation.
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(CI, 48%-82%), respectively (Fig 6). Of the 42 venous
reconstructions, 25 (60%) were patent at last imaging
study (mean, 2.6 years; median, 1.6; range, 0.1-11.7). 
Femorofemoral saphenous vein grafts (Palma pro-
cedure). Four-year primary and secondary patency rates
of 18 saphenous vein crossover grafts were 77% (CI, 60%-
100%) and 83% (CI, 67%-100%), respectively. Thirteen
grafts (72%) were patent at last imaging, at an average of
2 years (median, 1.3; range, 4 months to 9.8 years).
Three of 12 Palma grafts without an initial AVF failed,
compared with two failures of six with an initial AVF (P =
not significant). Three failing Palma grafts had AVFs
added at a secondary procedure, with preservation of
patency in one.
Iliocaval and femorocaval bypass grafts. The pri-
mary and secondary patency rates of 13 iliocaval (n = 5)
and femorocaval (n = 8) bypass grafts at 2 years were 38%
(CI, 19%-76%) and 54% (CI, 33%-89%), respectively. Two
iliocaval bypass grafts occluded, one at 2 months and the
other at 1 year. Five of eight femorocaval grafts failed at
0.2, 9, 15, 15, and 22 months (mean, 12 months). The
patency rate of iliocaval and femorocaval grafts (54%) was
not significantly different from that of Palma grafts (83%)
at 2 years (P = .3, Fig 7). 
Spiral vein grafts. Four (67%) of six grafts were
patent at 2, 2, 4, and at 10 months after reconstructions. 
Cavoatrial grafts. Two cavoatrial bypass grafts, 1
ePTFE, and 1 spiral vein graft (mentioned previously),
were performed. The ePTFE graft was patent at 1 year,
and the spiral graft occluded at 3 months. 
Crossfemoral ePTFE grafts. All three ePTFE grafts
occluded early at 1, 2, and 12 months, despite an adjunc-
tive AVF.
Intraoperative factors for graft occlusion
Greater saphenous vein reconstructions had better
secondary patency than grafts with ePTFE (difference
approaching significance, P = .095). The use of an adjunc-
tive AVF was significantly associated with higher graft loss
(P = .010). This association remained significant when
graft salvage or delayed AVF was excluded from the com-
parison (P = .023).
Patient risk factors for graft occlusion
Patient factors were also evaluated to determine
causes of graft failure. No statistically significant associa-
tions were found with any patient factor. These sub-
groups were small, resulting in a high SE and limited
comparison. However, smokers had a 39% lower patency
rate at 2 years when compared with nonsmokers (46%
versus 85% at 2 years, P = .097). Twenty-one patients had
concomitant infrainguinal venous occlusive disease, and
10 of these patients had graft occlusion. Sixteen patients
had concomitant infrainguinal reflux, and six had graft
occlusions. Nine patients with Palma grafts had concomi-
tant infrainguinal venous occlusion; only two of these
grafts have failed.
Clinical outcome
Thirty-four patients were available for assessment of
benefit of venous reconstruction at a mean of 6 years.
Four (12%) patients had no signs of venous disease, 12
(35%) had persistent swelling, and only 2 (6%) had active
ulcers (Table I).
Outcome score improved for the entire group, to an
average score of 1 (mild improvement).12a Median outcome
score improved in patients with patent reconstructions (2,
Fig 4. Methods for reconstruction of the IVC and iliofemoral
veins with autologous vein. Reprinted with permission from the
Mayo Foundation.
Fig 5. Prosthetic reconstructions (ePTFE). Reprinted with per-
mission from the Mayo Foundation.
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moderate improvement; range 0-3), as compared with those
with failed grafts (0, no change; range, +2 to –2, P < .01).
Mean preoperative clinical severity score was 7 (n = 38;
range, 0-16), and mean postoperative score was 5.7 (n =
34; range, 1-16, NS). Improvement in clinical score was
significantly better in patients with patent grafts (n = 16;
mean, 3.6; median, 1.5; range, 4 to –13), as compared with
those with occluded grafts (n = 13; mean, 1.4; median, 0.0;
range, 9 to –4; P = .44; patients with acute venous trauma
excluded n = 5). Of patients with patent reconstructions,
nine had improvement (56%), and seven noted no change
or worsening scores (44%). Of those with graft occlusion
five noted improvement (38%), and eight had no change or
worsening scores (62%). Disability scores did not improve
(2.7 preoperative, 2.0 postoperative, NS).
Postoperative noninvasive venous studies showed
improvement in only two of 12 patients studied with
impedance plethysmography. Strain-gauge plethysmogra-
phy was performed postoperatively in 18 patients, and in
no patients did the 4-second venous drainage fraction
return to a normal value of more than 60%. The mean
time to plethysmographic investigation was 3.1 months
(median, 3.0; range, 5 days to 4.5 years). Of these seven,
the incidence of associated venous reflux was noted to be
less then the entire surgical cohort (43% vs 52%).
Late surgical interventions included ligation of an AVF
in 9 patients, graft revisions in 2, thrombectomy in 1, and
balloon angioplasty in 1. AVF closure in nine of 24 patients
was performed, on average, at 9 months (range, 48 days to
1.5 years). Three patients died during follow-up. One
patient died of complications caused by a fall at the age of 92
(11 years after reconstruction), and the other two patients
died because of transplant failure (1 kidney and 1 liver).
DISCUSSION 
Surgical reconstructions for venous occlusive disease
Fig 6. Cumulative primary and secondary patency rates of 42 venous reconstructions.
Fig 7. Cumulative secondary patency rates of saphenous vein crossover bypass grafts (Palma procedure) and ePTFE iliocaval and femoro-
caval bypass grafts.
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are rarely performed. Consequently, reliable data on long-
term patency, clinical outcome, and risk factors for graft
occlusion are scant. With the availability of minimally inva-
sive endovascular techniques, indications for and results of
surgical treatment have to be scrutinized to provide the
patient with realistic options for treatment of venous out-
flow obstructions.
Endovascular stents have been used with increasing
frequency for the treatment of iliac vein occlusion.7,16-19
Initial experience has been favorable, although failures are
not uncommon. Three of the patients reported here had
bypass grafts performed after failed iliac stents were placed
in them at other institutions.
In the last 40 years various surgical operations have
been used to treat patients with caval or iliofemoral venous
occlusive disease. In 1958, Palma was the first to use a
crossfemoral saphenous veno-venous bypass graft for uni-
lateral iliac vein obstruction.20 The Palma procedure was
popularized further in this country by Dale1 and was suc-
cessfully used later by others.2-6 There have also been small
series of patients reported in whom reconstructions were
performed with prosthetic materials for direct femoral and
iliocaval replacement.21-23 All of these reports of venous
reconstruction had highly variable reporting standards.
Eklof et al24 have rightly criticized the reports for being
anecdotal, having variable surgical criteria, lacking objec-
tive follow-up, and having poor life-table patency analysis.
Our report does attempt to overcome these criticisms.
However, the number of patients in the different groups of
reconstructions was low, and statistical analysis was limited
in most subgroups. Most important, our follow-up with
imaging studies was short; it averaged only 2.6 years.
Information on clinical outcome with a longer follow-up
could be obtained on most patients; however, this infor-
mation was not used to evaluate the grafts’ patency.
The Palma procedure has been reported by others to
have patency rates of 70% to 85% and clinical improve-
ments in 63% to 88% of patients after reconstruc-
tion.2,3,20,25-31 In a report by AbuRahma et al,29 imaging
studies were performed at follow-up in all patients, and
the 7-year cumulative patency rate was 75%. However, the
SE in this study was high, and only a small number of
patients were followed up beyond 5 years. Our results
confirm this with similar findings of a 4-year patency rate
of 83% in Palma reconstructions (Table II). Sixty-seven
percent of these patients also noted clinical improvement
by outcome score. Therefore, the Palma procedure con-
tinues to be our first treatment option for patients with
symptomatic unilateral iliac vein occlusion.
Graft material for large vein reconstruction continues
to be a problem, because the saphenous vein is frequently
small or diseased. In such cases the remaining options for
venous reconstruction include vascular prosthesis, arm
vein, or homograft. Lalka et al32 reported a mathematical
advantage for the use of ePTFE in crossfemoral venous
reconstructions. However, prosthetic grafts for venous
reconstruction have been noted to have a lower patency
because of increased thrombogenicity coupled with lower
flow rates in the venous system.33 Encouraged by the
excellent results (85% patency rate) of Gruss and
Hiemer,30 we have attempted ePTFE crossfemoral grafts
in three patients, without success. The number in this
group remains low, and we do not have enough data to
comment on the use of PTFE crossfemoral grafts. In con-
trast, direct iliocaval or femorocaval reconstructions in our
patients resulted in a 54% cumulative patency rate at 2
years, and 64% of patients noted clinical improvement.
Others have reported that iliac and femoral direct recon-
structions have patency rates of 88% to 100%.22,23
The alternative to prosthetic reconstruction is the use of
spiral vein grafts. If vein is available, a short spiral vein graft
may be the right choice for replacement of a short segment
of an injured femoral or iliac vein. External compression of
the graft and length limitations restrict the use of spiral vein
grafts for iliocaval and femorocaval applications. 
The use of an AVF is a debated topic in the literature,
with pros and cons discussed in experimental and clinical
reports.33,34 Our findings could be construed to suggest that
an AVF might have a negative effect on patency. We used
AVF selectively in patients who were at high risk for graft fail-
ure because of low flow in the vein graft or the use of a pros-
thetic graft in an unfavorable position (long femorocaval,
Table II. Results of femorofemoral saphenous vein crossover bypass graft (Palma procedure)
First author Year No. of limbs Follow-up (y) Imaging follow-up Patency (%) Clinical improvement (%)
Palma20 1960 8 Up to 3 13 n/a 88
Dale25 1979 48 Up to 12 n/a n/a 77
May26 1981 66 n/a n/a 73 n/a
Dale27 1983 56 n/a n/a n/a 80
Husni2 1983 85 0.5-15 n/a 70 74
Halliday3 1985 47 Up to 18 72 75 (5 y) 89
Danza28 1991 27 n/a n/a n/a 81
AbuRahma29 1991 24 5.5 100 75 (7 y) 63
Gruss30 1997 19 n/a n/a 71 82
Jost 2000 18 0.1-9.1 100% 82 (4 y) 67
Total 398 74 78
Adapted with permission from Gloviczki P, Cho JS. Surgical treatment of chronic deep venous obstruction. In: Rutherford RB, editor. Vascular surgery. 5th
ed. Philadelphia: WB Saunders Co; 2000. p. 2049-66.
n/a, Not available.
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iliocaval, or femorofemoral PTFE). Because these patients
have the highest risk of graft thrombosis, it is not surprising
that we found a higher rate of graft failure in this group. We
currently use an AVF for Palma grafts under these condi-
tions: graft flow less than 100 mL/min, saphenous vein less
than 5 mm in diameter, or an intraoperative pressure gradi-
ent less than 5 mm Hg. Large Palma grafts with flows above
100 mL/min are done without an AVF. We continue to use
AVF for all femorocaval and all longer iliocaval ePTFE grafts.
The fistula is taken down at 3 months for Palma grafts and
at 6 to 9 months in ePTFE grafts. When the patient has
good clinical results and no ill effects from the AVF, we occa-
sionally leave the AVF in indefinitely.
Successful revascularization resulted in improved clin-
ical outcome, as measured with the clinical severity score.
Also, the patients’ own perception of their condition
improved significantly, as noted with outcome scoring,
when we compared those who had patent grafts with
those who had failed grafts. There is increasing evidence
that venous reconstruction gives durable results, and with
patency there are lasting improvements in clinical markers
of disease regression and patient satisfaction in most
patients. We suspect that severe infrainguinal occlusion or
valvular incompetence is the cause of disease progression
despite a patent reconstruction, in a minority of patients.
Noninvasive plethysmographic data confirmed the
presence of venous obstruction or reflux preoperatively
and helped in the selection of patients for contrast venog-
raphy. However, plethysmographic data were not helpful
for following graft patency. The failure of reconstruction
to improve venous drainage fraction might be due to dis-
tal venous obstruction in the deep venous system or the
presence of venous hypertension induced by an AVF.
These confounding factors limit the value of strain-gauge
plethysmography as a postoperative screening tool for
graft occlusion. Currently, we recommend duplex ultra-
sound scan for graft surveillance, at 3, 6, and 12 months
postoperatively and then every 6 months for life.
In conclusion, our experience with large vein recon-
struction suggests that surgical bypass grafting for nonma-
lignant venous occlusion of the IVC and iliac and femoral
venous systems has a role in a select group of symptomatic
patients. Venous reconstruction offers reasonable (62%) 3-
year patency, with associated clinical improvements. The
Palma procedure with the use of autologous saphenous vein
had the best long-term patency rate, 83% at 4 years, whereas
the long-term success with ePTFE was only moderate. The
use of an AVF to improve patency remains controversial.
REFERENCES
1. Dale WA. Venous bypass surgery. Surg Clin North Am 1982;62:391-8.
2. Husni EA. Reconstruction of veins: the need for objectivity. J
Cardiovasc Surg 1983;24:525-8.
3. Halliday P, Harris J, May J. Surgery of the veins. In: Bergan JJ, Yao
JST, editors. Femoro-femoral cross over grafts (Palma operation): a
long-term follow-up study. Orlando: Grune & Statton; 1985.
4. O’Donnell TFJ, Mackey WC, Shepard AD, Callow AD. Clinical,
hemodynamic, and anatomic follow-up of direct venous reconstruc-
tion. Arch Surg 1987;122:474-82.
5. Raju S, Fredericks R. Venous obstruction: an analysis of one hundred
thirty-seven cases with hemodynamic, venographic, and clinical corre-
lations. J Vasc Surg 1991;14:305-13.
6. Gloviczki P, Pairolero PC, Toomey BJ, Bower TC, Rooke TW,
Stanson AW, et al. Reconstruction of large veins for nonmalignant
venous occlusive disease. J Vasc Surg 1992;16:750-61.
7. Elson JD, Becker GJ, Wholey MH, Ehrman KO. Vena caval and cen-
tral venous stenoses: management with Palmaz balloon-expandable
intraluminal stents. J Vasc Interv Radiol 1991;2:215-23.
8. Gloviczki P, Pairolero PC, Cherry KJ, Hallett JW Jr. Reconstruction
of the vena cava and of its primary tributaries: a preliminary report. J
Vasc Surg 1990;11:373-81.
9. Rhee RY, Gloviczki P, Luthra HS, Stanson AW, Bower TC, Cherry KJ
Jr. Iliocaval complications of retroperitoneal fibrosis. Am J Surg
1994;168:179-83.
10. Bower TC, Nagorney DM, Toomey BJ, Gloviczki P, Pairolero PC,
Hallett JWJ, et al. Vena cava replacement for malignant disease: is
there a role? Ann Vasc Surg 1993;7:51-62.
11. Bower TC, Nagorney DM, Cherry KJ Jr, Toomey B, Hallett JW Jr,
Panneton JM, et al. Replacement of the inferior vena cava for malig-
nancy: an update. J Vasc Surg 2000;31:270-81.
12. Porter JM, Moneta GL. Reporting standards in venous disease: an
update. International Consensus Committee on Chronic Venous
Disease. J Vasc Surg 1995;21:635-45.
12a. Nicolaides AN, et al. Classification and grading of chronic venous dis-
ease in the lower linbs: a consensus statement. In Gloviczki P, Yao JST,
editors. Handbook of venous disorders: guidelines of the American
Venous Forum. London: Chapman and Hall Medical; 1996. p. 652-60.
13. Kaplan ER, Meier P. Nonparametric estimation from incomplete obser-
vations. Journal of the American Statistical Association 1958;53:457-81.
14. Peto R, Peto J. Asymptotically efficient rank invariant procedures.
Journal of the Royal Statistical Association 1972;135:185-207.
15. Rosfors S, Ahlstrom H, Boccalon H, Nilsson S, Partsh H, Rooke TW,
et al. Computerized strain-gauge plethysmography using a capacitance
mode in the diagnosis of deep venous thrombosis. Scope of
Phlebology and Lymphology 1996;2:8-12.
16. Blattler W, Blattler IK. Relief of obstructive pelvic venous symptoms
with endoluminal stenting. J Vasc Surg 1999;29:484-8.
17. Heniford BT, Senler SO, Olsofka JM, Carrillo EH, Bergamini TM.
May-Thurner syndrome: management by endovascular surgical tech-
niques. Ann Vasc Surg 1998;12:482-6.
18. Mickley V, Schwagierek R, Rilinger N, Gorich J, Sunder-Plassmann L.
Left iliac venous thrombosis caused by venous spur: treatment with
thrombectomy and stent implantation. J Vasc Surg 1998;28:492-7.
19. Binkert CA, Schoch E, Stuckmann G, Largiader J, Wigger P,
Schoepke W, et al. Treatment of pelvic venous spur (May-Thurner
syndrome) with self-expanding metallic endoprostheses. Cardiovasc
Intervent Radiol 1998;21:22-6.
20. Palma EC, Esperon R. Vein transplants and grafts in the surgical treat-
ment of the postphlebitic syndrome. J Cardiovasc Surg 1960;1:94-107.
21. Raju S. New approaches to the diagnosis and treatment of venous
obstruction. J Vasc Surg 1986;4:42-54.
22. Alimi YS, DiMauro P, Fabre D, Juhan C. Iliac vein reconstructions to
treat acute and chronic venous occlusive disease. J Vasc Surg
1997;25:673-81.
23. Dale WA, Harris J, Terry RB. Polytetrafluoroethylene reconstruction
of the inferior vena cava. Surgery 1984;95:625-30.
24. Eklof BG, Kistner RL, Masuda EM. Venous bypass and valve recon-
struction: long-term efficacy. Vasc Med 1998;3:157-64.
25. Dale WA. Reconstructive venous surgery. Arch Surg 1979;114:1312-8.
26. May R. The Palma operation with Gottlob’s endothelium preserving
suture. In: May R, Weber J, editors. Pelvic and abdominal veins: progress
in diagnosis and therapy. Amsterdam: Excerpta Medica; 1981. p. 192-7.
27. Dale WA. Crossover vein grafts for iliac and femoral venous occlusion.
Resident and Staff Physician 1983;29:58-63.
28. Danza R, Navarro T, Baldizan J. Reconstructive surgery in chronic
venous obstruction of the lower limbs. J Cardiovasc Surg 1991;32:
98-103.
29. AbuRahma AF, Woodruff BA, Lucente FC, Stuart SP, Boland JP. Factors
affecting survival of patients with ruptured abdominal aortic aneurysm in
a West Virginia community. Surg Gynecol Obstet 1991;172:377-82.
JOURNAL OF VASCULAR SURGERY
Volume 33, Number 2 Jost et al 327
30. Gruss JD, Hiemer W. Bypass procedures for venous obstruction:
Palma and May-Husni bypasses, Raju perforator bypass, prosthetic
bypasses, and primary and adjunctive arteriovenous fistulae. In: Raju
S, Villavicencio JL, editors. Surgical management of venous disease.
Baltimore: Williams & Wilkins; 1997. p. 289-305.
31. Gloviczki P, Cho JS. Surgical treatment of chronic deep venous
obstruction. In: Rutherford RB, editor. Vascular surgery. 5th ed.
Philadelphia: WB Sanders Co; 2000. p. 2049-66.
32. Lalka SG, Lash JM, Unthank JL, Lalka VK, Cikrit DF, Sawchuk AP,
et al. Inadequacy of saphenous vein grafts for crossfemoral venous
bypass. J Vasc Surg 1991;13:622-30.
33. Plate G, Hollier LH, Gloviczki P, Dewanjee MK, Kaye MP. Overcoming
failure of venous vascular prostheses. Surgery 1984;96:503-10.
34. Menawat SS, Gloviczki P, Mozes G, Whitley D, Anding WJ, Serry
RD. Effect of a femoral arteriovenous fistula on lower extremity
venous hemodynamics after femorocaval reconstruction. J Vasc Surg
1996;24:793-9.
Submitted Jun 13, 2000; accepted Oct 16, 2000.
Dr William C. Krupski (Denver, Colo). Dr Hobson, Dr Riles,
members, and guests.
I congratulate Dr Jost for an outstanding presentation. The
Mayo Clinic group is legendary for its extensive experience in treat-
ing venous disease. For that matter, reports of that institution con-
sistently describe enormous numbers of patients, often the largest
series of any given disorder. In that tradition, today’s description of
42 patients undergoing 44 reconstructions of the venous system
over a 14-year period is an impressive collection of cases. I tell the
residents that often such papers can be labeled “Look how good I
can do it” articles, reporting results that seemingly cannot be dupli-
cated by others. The presentation today is refreshing in that the
authors have described bad outcomes as well as good ones, with
only one in two patients enjoying 3-year graft patency.
To say this series of patients is a mixed bag is an understate-
ment. In their zeal to give us large numbers of patients to guide
our practices, the authors have combined apples, oranges, and
pomegranates. Some patients had Palma procedures, some had
spiral vein grafts, some had femoral or iliocaval PTFE grafts, some
had PTFE crossfemoral grafts, and one or two patients had other
procedures. Some patients had adjunctive arteriovenous fistulas,
some didn’t, and some had salvage AV fistulas. Some patients had
measurements of preoperative and postoperative pressure gradi-
ents and flow, and some didn’t. Although almost all patients had
postoperative anticoagulation, we are provided no information
regarding therapeutic INRs. When I tried to tie all this into a
treatment algorithm, I’m afraid I became hopelessly confused.
The Palma operation seemed to work well. In the 18 patients
who were candidates for this operation, 4-year patency was 82%.
Except for this operation, however, I fear I would not be enthu-
siastic about offering one of my patients any of these procedures.
Although one in two patients having other operations may enjoy
3-year patency, it is unclear how to choose which of the two
patients will benefit. I am left with Dr Wylie’s former teaching:
“Don’t operate on veins except to remove the varicose ones.”
Much ado is made in this presentation about the correlation
of clinical improvement and patency rates. I would point out,
however, that the patients could not be blinded to their own
patency data. A patient can see and hear the duplex or venogram
results of his or her postoperative study, and it would be a natural
tendency for those patients with patent reconstructions to think
they are doing better, whereas for those with failed grafts to
assume they are doing poorly. The thinking goes “My graft has
occluded, so I must be worse.” In that regard, the authors admit
that only a fraction of patients studied had objective improvement
in venous function by impedance plethysmography.
Finally, my greatest criticism of this report is the absence of
any type of control group. Of over 8000 patients seen at the Mayo
Clinic for venous insufficiency during the study period, 73 were
identified to have venous obstruction. We are not informed how
many of the 8000 had venous imaging studies. It is hard to believe
that only 73 of the 8000 had venous obstructions. Slightly over
half of the 73 patients identified underwent operation. The
authors provide no guidance regarding how they chose to operate
and not operate on these patients. Importantly, they provide no
DISCUSSION
information about those patients who were treated nonoperatively.
I would argue that optimization of conservative management
might have provided comparable improvement in clinical scores.
I would like Dr Jost to address the criticisms I have raised.
And I have only one specific question for him. What would you
recommend that we do with the middle-aged active patient who
has significant leg swelling, moderate discomfort, but no active
ulcers, and ultrasound findings of occlusion of the ipsilateral iliac,
common femoral, and proximal superficial vein? Should we oper-
ate? And if so, exactly what operation should we perform?
Again, Dr Jost, I think you did a great job with this presenta-
tion, and I thank the Society for the privilege of commenting on it.
Dr Corey J. Jost. Thank you, Dr Krupski, for your thoughtful
and poignant critique.
In response to your first critique regarding the collage of this
study, we felt it was important, because surgical intervention for
venous disease is rarely performed. We report the entire group so
that people have an idea of general overall patency or survival
analysis of interventions for venous disease.
With regard to therapeutic or postoperative anticoagulation,
we aim for a target of an INR of 2 to 3 in our patients, and all
patients but one were discharged from the hospital on oral anti-
coagulation. Recommendations for lifelong anticoagulation were
in all patients with PTFE grafts and/or patients with autologous
reconstructions who have a history of hypercoagulability or pre-
vious recurrent deep venous thrombosis.
As far as the treatment algorithm goes, our first option in a
patient who’s a good operative risk, with significant persistent
symptoms despite maximal conservative therapy is the Palma pro-
cedure. In patients who are good operative risks who do not have
an adequate vein or some other contraindication to the Palma
procedure, we do consider these other reconstructions.
In regard to functional assessment by plethysmography, we
found this technique helpful in screening patients preoperatively
for possible venographic evaluation. However, we were disap-
pointed with our results in changes in patients after surgery, and
we saw a small fraction of patients that had improvement to nor-
mal values with plethysmography. So we do not use this for a
screening technique, but we use duplex ultrasonography.
As far as outcome analysis, the outcome that was expressed
here was in terms of severity score as per the recommendations of
the Joint Vascular Society. This outcome analysis is not dependent
on the patients’ perception of their care but actual scores based
on venous ulceration, edema, and pain.
With concern of the control group, this is a small set of
patients, and all of our patients had failed conservative therapy and
presented for this reconstruction. It isn’t a prospective, random-
ized study, but yet a descriptive one of this small group of patients.
And lastly, with your patient with symptomatic venous obstruc-
tion involving the iliac, common femoral, and superficial femoral
vein, we would again treat this patient conservatively, initially. And if
there was any acute aspect to her thrombosis, we would aggressively
treat that. If the patient failed conservative mapping or had
intractable symptoms and had an excellent saphenous vein on that
affected extremity, we would consider a Palma procedure.
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Dr Ronald Bays (Saginaw, Mich). I have a couple of ques-
tions. I think it would be helpful to have pressure data for these
patients before and after your reconstructions. Is there a certain
pressure gradient that you would use to perform a bypass, and is
there a certain pressure gradient that would predict failure of the
graft or remaining patency of the graft?
My second question is, if you have one of those iliocaval recon-
structions and it subsequently thromboses, what do you do then?
Dr Jost. With regard to the first question, in a subgroup of
the patients we did have preoperative and postoperative pressure
gradient measurements. The mean preoperative pressure gradi-
ent was 10, and after reconstruction it was 4. I think a resting
venous pressure of 10 would be considered a concern. That, cou-
pled with positive plethysmography data and a venogram, would
be an indication.
With regard to failure, our numbers are too small to really
identify pressures because we only had that number in a subset to
find out what is a pressure gradient that would identify a graft
that’s at risk for failure. However, as we mentioned, with our indi-
cations for placement of an arteriovenous fistula for the Palma
procedure, we’re concerned if there is a gradient less than 5.
Dr Bays. And if the graft thromboses?
Dr Jost. If the graft thromboses, we’re aggressive in the early
postoperative period. We return these patients for a thrombec-
tomy. And also we did perform surveillance in the patients and
found several grafts that needed revision.
Dr Herbert J. Robb (Orchard Lake, Mich). Because of your
considerable experience with problems involving the vena cava, I
would like to ask you a what-would-you-have-done question. It
was five o’clock in the afternoon. You were called to the operating
room to assist with the problem. The patient had donated her right
kidney for her daughter that morning. Bleeding had been difficult
to control. The vena cava was now totally occluded at the level of
the left renal vein. It looked as if the kidney donor would lose both
kidneys and perhaps have many complications. To make a long
story short, we moved 2 in of lower vena cava up to replace the
occluded vein and attached the left renal vein to it. A Dacron graft
was used to replace the lower vena cava. It did not thrombose. The
patient has no complications. What would you have done? 
Dr Jost. I think you’ve given an excellent description of what
we would have done. I think that’s a good reconstruction. And in
that position, we anticipate that that graft would do well with the
high flows.
Dr Peter F. Lawrence (Irvine, Calif). I enjoyed your presenta-
tion. Just one brief question about the patients who had a suc-
cessful patent graft. You showed a dramatic picture of reduction
of edema, but I can’t help but comment about the amount of
hyperpigmentation that appeared in that particular patient. My
question relates to the aspects of the patient’s initial indications
that improve. Is it the swelling? Is it the pain? Is it the edema? I
know that their clinical grades improve, but were there specific
areas that improved and some areas that deteriorated that would
lead to the hyperpigmentation that you showed?
Dr Jost. I appreciate the comment. Unfortunately, in that patient
that preoperative image was obtained 2 years before reconstruction.
I have a picture of him at reconstruction with a completely brawny
limb, but not with that level of edema. So his lipodermatosclerosis
and pigmentation had all occurred prior to reconstruction.
